Emergent BioSolutions (EBS) Net Income Growth (1y) (2012 - 2026)
Emergent BioSolutions (EBS) Net Income Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -105.67% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -1,401.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,401.67% |
| Mar 31, 2026 | -90.00% |
| Dec 31, 2025 | -74.44% |
| Sep 30, 2025 | -55.40% |
| Jun 30, 2025 | 95.76% |
| Mar 31, 2025 | 655.56% |
| Dec 31, 2024 | 36.77% |
| Sep 30, 2024 | 143.58% |
| Jun 30, 2024 | -8.30% |
| Mar 31, 2024 | 104.83% |
| Dec 31, 2023 | 26.12% |
| Sep 30, 2023 | -202.41% |
| Jun 30, 2023 | -363.48% |
| Mar 31, 2023 | -4,932.43% |
| Dec 31, 2022 | -137.66% |
| Sep 30, 2022 | -166.36% |
| Jun 30, 2022 | -1,326.09% |
| Mar 31, 2022 | -105.31% |
| Dec 31, 2021 | -4.41% |
| Sep 30, 2021 | -182.78% |